Edwin is a healthcare journalist with a passion for data and analysis. He graduated with a master's degree in biomedical sciences and spent some time in postgraduate research before moving into journalism. Edwin's skills in data science and scientific analysis allow him to identify trends, develop insights, and tell compelling stories using data.
Latest from Edwin Elmhirst
The pharmaceutical industry continues to experience significant shifts in sales performance, with some companies achieving remarkable growth while others face stagnation or decline.
In Vivo looks at the therapies projected to lead global sales by 2030. These frontrunners not only reflect advances in innovation but also shifting priorities in chronic disease management.
As blockbuster drugs lose patent protection and sales decline, big pharma companies must replenish aging portfolios with innovative therapies. Some, like Eli Lilly and Novo Nordisk, are rising through new drug launches while others are increasingly reliant on older assets.
As analysts disagree over the future commercial performance of major late-stage therapies, In Vivo looks into the polarized debate surrounding five blockbuster assets.
Dupixent’s success across eight indications is a model other drugmakers would like to replicate. R&D leaders at Sanofi and Regeneron reflect back on the development strategy that built the $15bn product.
By 2030, the pharmaceutical company leaderboard will be transformed as incretin-based therapies propel Eli Lilly and Novo Nordisk to the top, while companies reliant on aging blockbuster drugs see their dominance wane.